Literature DB >> 10502275

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

K Erles1, P Sebökovà, J R Schlehofer.   

Abstract

In view of presumed non-pathogenicity, tumor suppressive properties, and site-specific integration of the viral genome the human parvovirus, adeno-associated virus (AAV) has gained great interest as a gene transduction vector. Data on the seroprevalence of antibodies to AAV vary between reports, probably due to the different serological methods used. In order to understand better the immune response to AAV during natural infection, sera from different age groups and various geographical regions were compared for AAV antibodies using an ELISA. The data show that the prevalence of antibodies to AAV is similar in Europe (Germany, France, and Switzerland), Brazil, and Japan, indicating worldwide infection. It was confirmed that infection takes place during childhood. However, declining seropositivity thereafter and a second increase of seropositivity after 30 years of age suggests reinfection or reactivation of latent virus in particular as the prevalence of IgM antibodies in adults is relatively high. Furthermore, pregnant women were found to be significantly more frequently seropositive than non-pregnant controls, hinting at a reactivation of persistent AAV (up to 80% of women carry AAV in genital tissue) in specific hormonal conditions, e.g., pregnancy. Cross-reaction of serum antibodies with the different AAV types (defined by complement fixation) was observed by ELISA and neutralization tests confirming earlier results. The results suggest an unstable AAV antibody response allowing lifelong reinfection or reactivation of persisting virus possibly due to partial immunotolerance after an infection in utero, at delivery or during early infancy. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502275     DOI: 10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  100 in total

Review 1.  Adenoassociated virus vectors for genetic immunization.

Authors:  Selvarangan Ponnazhagan
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain.

Authors:  Mihail Y Mastakov; Kristin Baer; C Wymond Symes; Claudia B Leichtlein; Robert M Kotin; Matthew J During
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

3.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

4.  Cloning and characterization of a bovine adeno-associated virus.

Authors:  Michael Schmidt; Hisako Katano; Ioannis Bossis; John A Chiorini
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

5.  Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?

Authors:  Kenneth I Berns; Barry J Byrne; Terence R Flotte; Guangping Gao; William W Hauswirth; Roland W Herzog; Nicholas Muzyczka; Thierry VandenDriessche; Xiao Xiao; Sergei Zolotukhin; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2015-12       Impact factor: 5.695

6.  Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.

Authors:  B Greenberg; J Butler; G M Felker; P Ponikowski; A A Voors; J M Pogoda; R Provost; J Guerrero; R J Hajjar; K M Zsebo
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

Review 7.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

8.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

9.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

10.  Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates.

Authors:  Hemraj B Dodiya; Tomas Bjorklund; James Stansell; Ronald J Mandel; Deniz Kirik; Jeffrey H Kordower
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.